{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:17:15Z","timestamp":1761488235059},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.bcp.2009.04.007","type":"journal-article","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T04:15:18Z","timestamp":1239768918000},"page":"249-260","source":"Crossref","is-referenced-by-count":20,"title":["STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner"],"prefix":"10.1016","volume":"78","author":[{"given":"Jonathan T.","family":"Sims","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sourik","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leann S.","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris J.","family":"Holler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Sil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Plattner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bcp.2009.04.007_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1042\/BC20080020","article-title":"Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells","volume":"100","author":"Sirvent","year":"2008","journal-title":"Biol Cell"},{"issue":"49","key":"10.1016\/j.bcp.2009.04.007_bib2","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1038\/sj.onc.1203878","article-title":"Regulation of cell death by the Abl tyrosine kinase","volume":"19","author":"Wang","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2009.04.007_bib3","series-title":"Chronic myeloid leukaemia: biology and treatment","first-page":"19","article-title":"BCR-ABL protein domain, function, and signaling","author":"Pendergast","year":"2001"},{"key":"10.1016\/j.bcp.2009.04.007_bib4","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/sj.onc.1205317","article-title":"Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease","volume":"21","author":"Scheijen","year":"2002","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bcp.2009.04.007_bib5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/ajh.20117","article-title":"ABL oncogene amplification with p16(INK4a) gene deletion in precursor T-cell acute lymphoblastic leukemia\/lymphoma: report of the first case","volume":"76","author":"Kim","year":"2004","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.bcp.2009.04.007_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor, imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2009.04.007_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bcp.2009.04.007_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev.med.48.1.353","article-title":"The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents","volume":"48","author":"Rowinsky","year":"1997","journal-title":"Annu Rev Med"},{"issue":"10","key":"10.1016\/j.bcp.2009.04.007_bib9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2009.04.007_bib10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2009.04.007_bib11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1179\/joc.2008.20.5.551","article-title":"The Renaissance of platinum-based chemotherapy for metastatic breast cancer","volume":"20","author":"Meriggi","year":"2008","journal-title":"J Chemother"},{"issue":"11","key":"10.1016\/j.bcp.2009.04.007_bib12","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1158\/0008-5472.CAN-06-0734","article-title":"Activation of abl tyrosine kinases promotes invasion of aggressive breast cancer cells","volume":"66","author":"Srinivasan","year":"2006","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.bcp.2009.04.007_bib13","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/sj.onc.1210714","article-title":"Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival","volume":"27","author":"Srinivasan","year":"2008","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.bcp.2009.04.007_bib14","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1111\/j.1742-4658.2005.04864.x","article-title":"Poly(ADP-ribose). The most elaborate metabolite of NAD+","volume":"272","author":"Burkle","year":"2005","journal-title":"Febs J"},{"issue":"2","key":"10.1016\/j.bcp.2009.04.007_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc1275","article-title":"The STATs of cancer\u2014new molecular targets come of age","volume":"4","author":"Yu","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2009.04.007_bib16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/01.cad.0000173476.67239.3b","article-title":"PI3K\/Akt\/mTOR pathway as a target for cancer therapy","volume":"16","author":"Morgensztern","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bcp.2009.04.007_bib17","first-page":"945","article-title":"Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention","volume":"8","author":"Buettner","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bcp.2009.04.007_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0960-0760(01)00189-3","article-title":"The role of mitogen-activated protein (MAP) kinase in breast cancer","volume":"80","author":"Santen","year":"2002","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"9","key":"10.1016\/j.bcp.2009.04.007_bib19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.onc.1203412","article-title":"Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2\/p52 and for Bcl-3","volume":"19","author":"Cogswell","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2009.04.007_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/384273a0","article-title":"Three distinct signalling responses by murine fibroblasts to genotoxic stress","volume":"384","author":"Liu","year":"1996","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bcp.2009.04.007_bib21","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells","volume":"103","author":"Chu","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2009.04.007_bib22","first-page":"188","article-title":"Pharmacologic mitogen-activated protein\/extracellular signal-regulated kinase kinase\/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr\/Abl-expressing human leukemia cells","volume":"62","author":"Yu","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2009.04.007_bib23","unstructured":"Traynor JR. In Katzung 3rd, BG, editor. Basic and clinical pharmacology. Prentice\/Hall International; 1987 [pound 26.25. J Pharm Biomed Anal 1988;6(5):527]."},{"issue":"5","key":"10.1016\/j.bcp.2009.04.007_bib24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/ijc.20652","article-title":"In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy","volume":"113","author":"Decaudin","year":"2005","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2009.04.007_bib25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/01.mlg.0000225895.40732.52","article-title":"STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro","volume":"116","author":"Wang-Rodriguez","year":"2006","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.bcp.2009.04.007_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-2-1","article-title":"Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro","volume":"2","author":"Zhang","year":"2003","journal-title":"Mol Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2009.04.007_bib27","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00432-008-0408-0","article-title":"Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects","volume":"134","author":"Mundhenke","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.bcp.2009.04.007_bib28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4161\/cbt.3.4.727","article-title":"Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571","volume":"3","author":"Bellone","year":"2004","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"10.1016\/j.bcp.2009.04.007_bib29","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2009.04.007_bib30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","article-title":"Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps","volume":"4","author":"Burger","year":"2005","journal-title":"Cancer Biol Ther"},{"issue":"12","key":"10.1016\/j.bcp.2009.04.007_bib31","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.4161\/cc.3.12.1331","article-title":"Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib","volume":"3","author":"Burger","year":"2004","journal-title":"Cell Cycle"},{"issue":"9","key":"10.1016\/j.bcp.2009.04.007_bib32","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2009.04.007_bib33","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","article-title":"Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro","volume":"64","author":"Houghton","year":"2004","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.bcp.2009.04.007_bib34","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1158\/1078-0432.CCR-06-1599","article-title":"The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2","volume":"13","author":"Liu","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bcp.2009.04.007_bib35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0895-3988(08)60044-6","article-title":"Breast cancer resistance protein expression and 5-fluorouracil resistance","volume":"21","author":"Yuan","year":"2008","journal-title":"Biomed Environ Sci"},{"issue":"5","key":"10.1016\/j.bcp.2009.04.007_bib36","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/1535-7163.MCT-04-0291","article-title":"The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites","volume":"4","author":"Pratt","year":"2005","journal-title":"Mol Cancer Ther"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209002925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209002925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T08:26:42Z","timestamp":1545294402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295209002925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0006295209002925"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2009.04.007","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}